Bertelsen J, Herskind A M, Sprogøe Jakobsen U, Hegedüs L
Department of Internal Medicine and Endocrinology, Odense University Hospital, Denmark.
Thyroidology. 1992 Dec;4(3):103-6.
The effect of a standard 555 MBq 131I dose in ablating the thyroid gland was investigated in 116 consecutive hyperthyroid patients. Fifty-one had Graves' disease, 50 a multinodular toxic goitre and 15 had a solitary toxic nodule. 555 MBq 131I was given regardless of size or type of the gland and severity of the disease. Within one year after this dose hypothyroidism was induced in 41% of patients with Graves' disease, but in only 13% with a solitary toxic adenoma, and 6% with a multinodular gland. Forty-eight percent of the patients with a multinodular gland, 33% with Graves' disease and 13% with a solitary toxic nodule were still hyperthyroid. Since this so called ablative treatment only accomplishes hypothyroidism in 26/116 (23%) of our patients and results seem unpredictable 131I treatment adjusted according to gland size and type aiming at achieving euthyroidism could be contemplated.
在116例连续的甲状腺功能亢进患者中，研究了标准剂量555MBq的131I对甲状腺的消融效果。其中51例患有格雷夫斯病，50例患有多结节毒性甲状腺肿，15例患有单个毒性结节。无论腺体大小、类型及疾病严重程度如何，均给予555MBq的131I。给予该剂量后一年内，41%的格雷夫斯病患者发生了甲状腺功能减退，但单个毒性腺瘤患者中仅有13%，多结节腺体患者中仅有6%发生甲状腺功能减退。多结节腺体患者中有48%、格雷夫斯病患者中有33%、单个毒性结节患者中有13%仍为甲状腺功能亢进。由于这种所谓的消融治疗仅使我们116例患者中的26例（23%）发生了甲状腺功能减退，且结果似乎不可预测，因此可以考虑根据腺体大小和类型调整131I治疗，以实现甲状腺功能正常。
